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Many of the fundamental molecular mechanisms underlying tumor biology remain elusive and, 
thus, developing specific anticancer therapies remains a challenge. The recently discovered 
relationships identified among telomeres, telomerase, aging, and cancer have opened a new avenue 
in tumor biology research that may revolutionize anticancer therapy. This review summarizes the 
critical aspects of telomerase biology that underpin the development of novel telomerase-targeting 
therapies for malignant diseases, and special regard is given to the aspects of telomerase that make 
it such an appealing target, such as the wide-spread expression of telomerase in cancers. Despite 
significant progress, issues remain to be addressed before telomerase-based therapies are truly 
effective and we include critical discussion of the results obtained thus far. 
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Telomeres and telomerase 
 
A classic cancer hallmark is the ability of malignant cells to proliferate indefinitely [1]. This is in 
stark contrast to the limited number of cell divisions normal somatic cells undergo (the so-called 
Hayflick limit) [2]. Today we know this restriction is due to the shortening of telomeres [3], the 
tandem repeat DNA sequence TTAGGG that associates with telomere binding proteins [4] to form 
the shelterin complex (Figure 1). This structure protects linear chromosome ends from recognition 
as DNA double-strand breaks (DSBs), thus contributing to genomic stability [5,6]. The four-
stranded planar stacks that form within or between the guanine-rich single-strand of telomeric DNA 
(so-called G-quadruplexes) are a second conformation that protects the ends of DNA [7]. Due to the 
inability of the DNA replication machinery to copy the extreme ends of chromosomes, a 
phenomenon referred to as the "end replication problem", most human somatic cells show 
progressive telomere erosion as a consequence of ongoing cell division. Once a subset of telomeres 
reach a critically shortened length, a DNA damage response (DDR) is induced that triggers p53-
dependent G1/S cell cycle arrest, known as replicative senescence. Therefore, telomeres function 
not only as "caps" to protect chromosome ends from events such as fusion, degradation, or 
recombination but also serve as a biological clock to gauge (replicative) cell aging.  
While looking for the solution to the "end replication problem", investigators discovered the 
holoenzyme telomerase [8], a ribonucleoprotein that synthesizes the hexameric tandem repeats onto 
the ends of eukaryotic chromosomes. The telomerase complex consists of two components, the 
reverse transcriptase catalytic subunit (TERT) and the telomerase RNA component (TERC). 
Telomerase helps maintain genome integrity as well as replication capability in both embryonic 
stem cells and proliferating progenitor cells derived from quiescent normal stem cells (e.g., male 
germ-line spermatocytes), but it is silent in somatic cells, which make up the vast majority of 
human tissues [9]. 
 
 
Telomerase and cancer 
 
In the early 1990s, the discovery of a relationship between telomeres, telomerase, aging, and cancer 
[10,11] opened an entirely new avenue in tumor biology research, with potentially revolutionary 
implications for anticancer therapy [12,13]. Unlike most normal human cells - which lack 
telomerase activity and experience telomere shortening with each cell division until they enter 
replicative senescence - cells deficient in cell cycle checkpoints (e.g., early stage malignant cells 
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that lack p53, p16, or ARF/CDKN2A) escape replicative senescence and continue to divide (Figure 
1). These cells eventually enter a second growth arrest state (crisis) when many shortened 
chromosome ends fuse, leading to cycles of chromosome bridge–breakage–fusion that almost 
universally result in apoptosis. In human cells, these two mechanisms of restricting cell growth 
(senescence and crisis) are potent mechanisms for protecting against cancer. Most human cells 
remain in this crisis period, with cell growth being balanced by cell death, but on rare occasions a 
cell acquires a mechanism, such as telomerase expression, that can maintain or lengthen telomeres. 
Cells that have escaped crisis are usually characterized by two hallmarks: telomere stability and the 
reactivation of telomerase expression. This rare type of cell can then grow continuously (i.e., it 
becomes immortal), and this is believed to be a pivotal step in carcinogenesis. Indeed, in the 
presence of an intact p53 pathway, mice that lack telomerase activity are resistant to cancer 
development [14-16], whereas forced TERT overexpression in different mouse models is associated 
with an increased incidence of spontaneous tumors [17,18].  
In addition to its canonical role in maintaining telomere length in malignant cells, 
telomerase has recently been recognized to interfere with extra-telomeric tumor-promoting 
pathways [9]. For instance, TERT can function as a transcriptional modulator of Wnt/beta-catenin 
signaling by serving in combination with BRG1 (a SWI/SNF-related chromatin remodeling protein) 
as part of a beta-catenin transcriptional complex. Additional evidence also supports the role of 
telomerase in the regulation of apoptosis in a non-canonical, telomere-independent manner. The 
overexpression of TERT - which contains a mitochondrial localization signal peptide - suppresses 
programmed cell death, and TERT downregulation enhances the mitochondrial apoptotic pathway 
by the post-translational activation of the proapoptotic factor Bax. In light of the pivotal importance 
of both the Wnt/beta-catenin pathway and apoptosis in cancer biology, these experimental findings 
strengthen the hypothesis that telomerase has a central role in cancer development and progression.  
Ex vivo studies carried out with human tissues have shown telomerase to be expressed in 
approximately 90% of all malignant tumors [19,20], which makes it a potential biomarker for most 
cancers. Furthermore, telomerase levels correlate with the severity of patient prognosis for a variety 
of tumor types, and so it may become a predictor of clinical outcome in different settings [21,22]. 
Finally, epidemiological studies on the relationship between cancer incidence and polymorphisms 
in the 5p15.33 locus, which encodes TERT, strongly suggest that variability of the TERT gene 
sequence affects individual cancer predisposition [23], although the molecular mechanisms 





Telomerase targeting anticancer strategies 
 
Considering the evidence mentioned above linking telomerase activity to tumor 
development and progression, researchers are devising a variety of methods to target telomerase as 
a novel therapy against cancer [12,13] (Figure 2). As for any targeted approach, telomerase-based 
antitumor strategies hinge upon specificity for the target, which allows the treatment to affect 
malignant cells with little, or ideally no, toxicity for healthy tissues. Telomerase is activated in the 
majority of human tumors [13,19], and the 5p15.33 locus is frequently amplified in many types of 
cancer [24], which provides malignant cells with the capacity to divide indefinitely. Overall, these 
observations suggest that targeted inhibition of telomerase could trigger critically short telomeres 
and, ultimately, lead to a selective loss of cell viability in the tumor. However, telomerase 
expression is also observed in a variety of normal tissues (e.g., bone marrow blood cells, basal layer 
skin cells, and epithelial cells of mucosae), at least during the S-phase of the cell cycle when 
telomerase activity is mainly growth-regulated [25-28]. In fact, actively dividing cells maintain 
strictly regulated telomerase expression and activity, whereas telomerase expression is repressed in 
differentiated somatic tissues. By contrast, most tumor cells show a high level of telomerase 
activity, and tumor cells - upon oncogenic stimuli - accelerate their proliferation rate, consequently 
decreasing the length of their telomeres and explaining why telomeres are usually shorter in 
malignant cells compared with surrounding healthy tissues [13,29-32]. As a consequence, normal 
progenitor cells and stem cells, having relatively long telomeres and undergoing less frequent 
mitosis, should be more resilient to the therapeutic inhibition of telomerase compared with 
malignant cells. This consideration, along with telomerase overexpression in malignant versus 
healthy tissues, is the fundamental rationale for the telomerase-targeted anticancer strategies 
discussed below.  
 
Small molecule inhibitors 
The most intuitive approach for therapeutically exploiting the role of telomerase in cancer biology 
is to inhibit its enzymatic activity. This can be achieved using small synthetic molecules such as 
BIBR1532 (2-[[E]-3-naphthalene-2-yl-but-2-enoylamino]-benzoic acid), a noncompetitive inhibitor 
of both TERT and TERC [33]. In a range of human cancer cell lines derived from both solid tumors 
and hematological malignancies, in vitro treatment with this drug reduces telomere length, inhibits 
cell proliferation, leads to cellular senescence, and - at higher doses - is cytotoxic [34,35]. When 
cancer cells pretreated with BIBR1532 are implanted into nude mice, tumor growth is significantly 
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delayed compared with a control group, although additional treatment does not produce any further 
advantage [34]. Interestingly, the cytotoxic effect appears to be selective for malignant cells of the 
hematopoietic system because the proliferative capacity of normal CD34(+) cells from cord blood 
and leukapheresis samples is not affected by treatment with BIBR1532 [35].  
 
An indirect strategy for inhibiting telomerase activity is stabilization of G-quadruplexes, which 
prevents TERC from recognizing the hydroxyl group at the 3' end of the unfolded, single-stranded 
telomere overhang [7]. So-called G-quadruplex ligands are small synthetic molecules that stabilize 
telomere quadruplex structures, thus inhibiting telomerase activity [36-38]. The macrocyclic 
compound telomestatin, derived from Streptomyces anulatus, is the best characterized of these 
ligands and potently inhibits telomerase [39]. This drug, as well as others such as the tri-substituted 
acridine compound BRACO19, have promising anticancer effects both in vitro and in vivo in 
preclinical models [40-42], including the eradication of cancer stem cells by the induction of 
apoptosis [43]. 
The clinical testing of small molecule telomerase inhibitors is hampered by poor 
pharmacokinetic characteristics, such as limited solubility in water, which requires the addition of 
solubilization enhancers or drug carrier systems to make these compounds bioavailable. Although 
BRACO19 is more soluble than other small molecule inhibitors, its use is still limited by the low 
permeability that renders it unable to pass through biological barriers in airways or intestinal 
epithelial cell cultures in vitro [44]. This key issue is underscored by an elegant in vivo experiment 
demonstrating that oral administration of BRACO19 has no therapeutic effect, whereas 
intraperitoneal injection leads to significant tumor shrinkage [42]. More hydrophobic compounds 
have been designed to circumvent this issue, including RHPS4 [45] and quarfloxin/CX-3543; 
quarfloxin has been evaluated in a phase II clinical trial as a treatment for neuroendocrine tumors 




Active immunization (i.e., vaccination) against tumor associated antigens (TAAs) has been long 
proposed as a "smart" therapeutic approach against cancer, although the results in clinical settings 
have so far been disappointing [47,48]. Whereas most TAAs are specific for a tumor type (e.g., 
carcino-embryonic antigen [CEA] for gastrointestinal carcinomas or tyrosinase for melanoma), 
telomerase-based immunotherapy may be suitable for a variety of malignancies due to the almost 
ubiquitous expression of telomerase in malignant cells [49]. TERT-derived peptides can be 
 7 
recognized by cytotoxic CD8+ lymphocytes in a MHC class I restricted fashion [50], and TERT-
based vaccination has been shown to lead to tumor regression in different preclinical models [51-
53] (reviewed in [49]).  
In the clinical setting, most patients affected with various solid tumors and vaccinated with 
telomerase peptides mount an immunological response, as assessed by the frequency of epitope 
specific CD8+ T-lymphocytes in the peripheral blood, with no high grade toxicity being observed. 
This response has been seen for both unmodified peptides, such as GV1001, a 16-mer TERT 
peptide that binds multiple HLA class II molecules and harbors putative HLA class I epitopes [54] 
as well as optimized telomerase peptides, including Vx-001, a 9-mer HLA-A*0201 restricted TERT 
cryptic peptide modified at position 572 to increase its immunogenicity [55]. Similar data have been 
described for patients with prostate cancer vaccinated with GRNVAC1, a preparation of mature 
autologous dendritic cells transfected with a TERT–LAMP (lysosomal associated membrane 
protein) fusion construct, with the LAMP domain facilitating lysosome targeting and processing of 
the TAA TERT [56]. Importantly, a complete tumor response has been recorded in a patient with 
pancreatic carcinoma vaccinated with dendritic cells transfected with TERT mRNA [57], and 
patients with an immunological response to TERT peptides (e.g., I540 [58] or Vx-001 [59]) have 
been shown to survive longer than non-responders in non-randomized studies [58,59]. Although a 
lack of both immune and tumor response has also been reported in patients with hepatocellular 
carcinoma and cutaneous T-cell lymphoma treated with GV1001 [60,61], ongoing trials are 
formally testing the hypothesis that telomerase can be an effective target for anticancer 





Despite the safety issues and the relatively recent implementation in the clinical setting, the gene 
therapy approach to human diseases has found its niche [62], although in the oncology field no such 
treatment has yet become the standard therapy for any tumor type [63-65]. Gene therapies involving 
TERT or TERC can be classified into two main types: (i) the inhibition of TERT or TERC 
expression/activity targeting their RNAs; or (ii) the utilization of TERT or TERC promoters to drive 
expression of exogenous vectors. In the first case, antisense oligonucleotides (ASOs, single-
stranded DNA or RNA sequences complementary to the target RNA), small interfering RNAs 
(siRNAs, double-stranded RNA molecules that regulate both mRNA degradation and mRNA 
translation by the RNA interference phenomenon), and ribozymes (RNA enzymes capable of 
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cleaving specific mRNAs) have been employed to specifically inhibit the activity or reduce the 
levels of TERT or TERC, which  ultimately lowers the enzymatic activity of telomerase. In a variety 
of preclinical models this approach not only leads to senescence and apoptosis of human cancer 
cells in vitro [66-69] but also to significant antitumor effects in vivo [66-68,70].  
Probably the most well-studied ASO in this context is imetelstat (also known as GRN163L), a lipid-
modified 13-mer oligonucleotide N3'->P5'-thio-phosphoramidate complementary to the template 
region of TERC [71]. After showing therapeutic potential in preclinical models [66,70], including 
an ability to target cancer stem cells [72,73], this telomerase inhibitor is currently being tested in 
clinical trials (see Table 1). 
 The second telomerase-based gene therapy approach exploits the TERT promoter to deliver 
"suicide" genes or oncolytic viruses selectively to malignant cells: as for telomerase-based 
immunotherapy, this strategy does not aim to inhibit telomerase activity but rather exploit 
telomerase overexpression in tumors. For instance, a viral vector genetically modified to encode a 
prodrug activating enzyme, such as carboxypeptidase G2 or cytosine deaminase, and to replicate 
only in TERT-overexpressing cells can be used to activate the effect of the cytotoxic prodrug, such 
as ZD2767P or 5-flucytosine, respectively, only in the tumor [74,75].  
Similarly, oncolytic viruses can be designed to induce virus-mediated lysis of tumor cells 
after selective viral propagation within the TERT-overexpressing tumor [76,77]. The latter strategy 
has already entered the clinical phase of experimentation with an attenuated adenovirus-5 vector 
(telomelysin/OBP-301) [78] in which the TERT promoter element drives the expression of E1A and 
E1B genes linked with an internal ribosome entry site (IRES). Telomelysin replicates efficiently 
and induces significant cell killing in a panel of human cancer cell lines, whereas replication and 
cytotoxicity are highly attenuated in normal human cells lacking telomerase activity [79]. 
 
 
Challenges and future perspectives 
 
Telomerase research has opened a promising avenue in the fight against cancer, and 
preclinical findings provide new hope for patients affected with malignant diseases. However, the 
clinical implementation of telomerase-based therapeutic strategies is proceeding at a pace slower 
than was probably expected [80]. Among the three randomized controlled phase III trials of 
therapies targeting telomerase, one was prematurely stopped based on a lack of survival benefit for 
patients undergoing vaccination with GV1001 followed by administration of gemcitabine, as 
compared with patients receiving chemotherapy alone (trial NCT00358566 at 
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www.clinicaltrials.gov), and two testing the efficacy of the GV1001 vaccine given after 
chemotherapy are ongoing (Table 1). The results of these latter studies are eagerly awaited to 
define the potential role of this therapeutic approach in prolonging patient survival. This apparent 
discrepancy between experimental and clinical data does not likely depend only on the intrinsic 
difficulty of testing novel cancer treatments in a clinical setting, but may also derive from many 
open questions regarding telomerase biology and targeting that need to be answered before the 
therapeutic potential can be fully exploited. 
 
The shortest telomere issue  
One of several open questions in the development of telomerase-targeting therapies remains 
‘what is the precise anticancer mechanism of telomerase inhibitors?’ Telomere shortening, which 
ultimately causes apoptosis of malignant cells, is generally believed to be the most relevant 
mechanism as it can be observed as a result of a variety of telomerase inhibition methods 
[66,67,70]. Nevertheless, in some models this rule does not apply [69,81,82], not only casting 
doubts on the way telomerase inhibitors act against cancer but also representing a serious hurdle in 
the search for predictors of tumor response. In fact, if the average telomere length consistently 
decreased upon administration of such drugs, its measurement might be proposed as a potentially 
useful biomarker for the early detection of tumor response (and thus drug effectiveness). However, 
since the shortest telomeres in a cell are those responsible for triggering a DNA damage checkpoint 
and/or genomic instability following telomerase inhibition [83], for the purposes of prediction it is 
much more informative to know the distribution of shortest telomeres in a tumor cell population (on 
a cell-by-cell basis) rather than to measure the average telomere length. Accordingly, only the 
development of reliable quantitative assays to measure the cell-based distribution of the shortest 
telomeres in a given cell population will allow oncologists to optimize the selection of cancer 
patients with the greatest likelihood of responding to telomerase inhibitors.  
Finally, because short telomeres drive genomic instability and facilitate clonal evolution [9], 
there is the theoretical possibility that telomerase inhibition might exacerbate this process, which 
ultimately might accelerate tumor progression. Therefore, investigators should take into 
consideration this potential caveat while dealing with telomerase inhibition as a novel anticancer 
therapy. 
 
The perfect target 
There also appears to be conflicting evidence regarding the most suitable telomerase component for 
targeting (i.e., TERT versus TERC). In a comparative study, ASO-mediated inhibition of TERT 
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induces growth arrest and apoptosis of human prostate cancer cells, whereas inhibition of the 
telomerase RNA component has no such effect [81]. Conversely, other investigators reported 
similar biological effects for both TERT and TERC inhibition, and the simultaneous inhibition of 
both components provided an additive effect [84]. Even more puzzling is the demonstration that in 
other experimental settings, for example when using the small molecule inhibitor BIBR1532 against 
leukemic cells, the enzyme activity of telomerase does not appear to be involved in the therapeutic 
effect of telomerase inhibition [35]. Clearly, only by defining the molecular events that lead to 
cancer cell death following telomerase targeting will enable investigators to make the most of anti-
telomerase therapies in the fight against cancer. 
 
Pharmacokinetic issues 
Another key issue in the development of telomerase-based antitumor strategies is the 
pharmacokinetic properties of molecules targeting telomerase. As mentioned above, small 
molecules inhibitors are often insufficiently hydrophobic and thus scarcely penetrate through cell 
membranes, strongly limiting their use in vivo. Antisense oligonucleotides, siRNAs, and ribozymes 
are even bigger molecules that often have even worse diffusion characteristics and require 
association with lipid carriers such as oligofectamine or lipofectamine to increase their penetration 
into malignant cells. However, the lipid carriers are associated with non-negligible toxic effects on 
healthy cells, and therefore other solutions are being assessed for human trials. For instance, lipid 
modification (i.e., conjugation with a palmitoyl moiety) significantly augments the bioavailability 
of imetelstat/GRN163L, an ASO resistant to nuclease activity due to thio-phosphoroamidate 
modification of its backbone [71] that is currently being tested in clinical trials (Table 1). Similarly, 
nanotechnologies are providing researchers with novel tools to enhance the bioavailability of 
telomerase-targeting drugs. For example, delivery of anti-TERT siRNA using N-(6-aminohexyl)-
carbamate-modified single-walled carbon nanotubes suppresses the growth of human tumor 
xenografts [68]. Nevertheless, the clinical use of this carrier system is probably limited by the lack 
of biodegradability and unclear toxicology of carbon nanotubes; this inconvenience might be 
overcome by biodegradable polyethylenimine(PEI)-based nanoparticles, as recently demonstrated 
for siRNA molecules targeting TERT that inhibit tumor growth in a xenograft model [85]. 
 
Combinatorial regimens 
As reported above, targeting telomerase with a variety of approaches can delay in vivo cancer 
growth in preclinical models. However, more pronounced anticancer effects such as shrinkage and 
possibly disappearance of already established tumor masses are desirable in the clinical setting. 
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Moreover, the lag phase between when the telomeres have shortened to their critical limit and the 
onset of cell senescence or apoptosis may take several weeks. To tackle these hurdles, the 
combination of telomerase-based treatments with established anticancer therapies appears to be a 
promising approach; in fact, preclinical evidence supports the idea of synergistic anticancer effects 
for all of the above mentioned telomerase targeting strategies with regimens already approved for 
human cancer treatment, including chemotherapeutic agents (e.g., etoposide [86], docetaxel [87], 
doxorubixin [88], paclitaxel [89]), monoclonal antibodies (e.g., anti-HER2 trastuzumab [90]), 
immunotherapy (e.g., anti-CTLA4 antibodies [91]), and radiotherapy [92]. Considering the 
potential benefit of combinatorial approaches, both telomerase inhibitors and telomerase-based 
vaccines are being tested as maintenance/consolidation regimens to prolong remission after 
standard chemotherapy in patients with advanced cancers (see Table 1). 
 
Safety issues 
Finally, safety concerns must also be considered. One issue not specifically linked to the target 
(telomerase) but to the vectors is the oncogenic potential of gene therapy approaches that hinge 
upon cell transfection with constructs encoded by viruses or plasmids  [62,93]. Although the risk of 
causing secondary neoplasms may be considered of minor relevance when the prognosis is poor 
(i.e., in case of metastasis), this issue becomes crucial in patients with early stage cancer. In 
addition, the specific side effects following the inhibition of telomerase activity, or its expression, in 
humans remain to be fully evaluated. As reviewed here, the differences in telomerase expression 
and telomere length in healthy versus malignant tissues may make telomerase the safest cancer 
target identified to date. Nevertheless, telomerase is important for the renewal capacity of normal 
stem and progenitor cells [94]. Moreover, telomere length in the bone marrow shortens with age 
and can be further eroded by anticancer chemotherapy [95]; therefore, a long-term adverse effect of 
telomerase-based cancer therapies on normal tissues cannot be excluded a priori. Thus far no 
evidence of toxicity of this type has been reported in any of the proliferative tissues (including bone 
marrow) analyzed in animal models or clinical trials. However, experience is still relatively limited, 
and thus exploratory biomarkers of telomere status in proliferative tissues are under evaluation and 
ongoing trials will need to monitor such potential effects on multiple normal tissues.  
 
Overall, the preclinical evidence strongly supports the therapeutic potential of telomerase based 
antitumor strategies and justifies further efforts for their clinical implementation. However, only by 
addressing the main issues mentioned above will investigators be able to assess whether the promise 
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BOX: Outstanding questions in the development of telomerase based anticancer therapies. 
 
- Do telomerase-based therapies really target the ‘Achilles' heel’ of cancer? That is, are 
telomerase functions indispensable for malignant cell survival? 
- Are telomerase-based therapies safe in humans, especially with respect to long-term effects 
of telomerase inhibition/targeting on healthy tissues? 
- What are the predictors of tumor response to therapies that target telomerase? In other 
words, can we select patients with a higher likelihood of responding to this novel anticancer 
approach?  
- Are there resistance mechanisms to telomerase-based therapies? Can these therapies select 
for tumor clones that downregulate telomerase expression (which would hamper telomerase-
based immunotherapy) or use alternative ways for lengthening telomeres (so-called ALT 
pathways)?  
- Is TERC a better target than TERT, or vice versa? 
- Are there telomerase inhibitors with better pharmacokinetic properties than currently 
available compounds? 
- Are telomerase-targeting therapies alone sufficient to defeat cancer? Will combinatorial 





Table 1: Ongoing clinical trials of telomerase-targeting anticancer therapies 
(www.clinicaltrials.gov) 
Identifier Tumor Design Intervention 
NCT01265927 Breast cancer 
(metastatic) 
Phase I GRN163L 
a
 (telomerase inhibitor) + trastuzumab (anti-
HER2 monoclonal antibody) 
NCT01342224 Pancreatic cancer 
(locally advanced) 
Phase I GV1001 (TERT-based vaccine) + chemoradiotherapy 
NCT01568632 Refractory solid tumors 
and lymphoma 
Phase I GRN163L 
a
 (telomerase inhibitor) 
NCT01579188 Non-small cell lung 
cancer (inoperable 
stage III)  
Phase III GV1001 (TERT-based vaccine) versus placebo (after 
curative intent chemoradiotherapy) 
NCT00573495 Breast cancer 
(advanced) 
Phase I TERT and Survivin peptides (vaccine) 
NCT01242930 Multiple myeloma 
(previously treated) 
Phase II GRN163L 
a
 (telomerase inhibitor) as maintenance 
therapy 




 GRN163L  
a
 (telomerase inhibitor) + paclitaxel (with or 
without bevacizumab) versus paclitaxel (with or without 
bevacizumab) alone  
NCT01137968 Non-small cell lung 
cancer (previously 
treated) 
Phase II GRN163L 
a
 (telomerase inhibitor) as maintenance 
therapy (standard of care versus standard of care + 
GRN163L) 
NCT00510133 Acute Myelogenous 
Leukemia 
Phase II GRNVAC1 (TERT-based vaccine) 
NCT01456065 Ovarian cancer 
(previously treated) 
Phase I TERT and Survivin peptide loaded dendritic cells 
(vaccine) 
NCT00978913 Breast cancer or skin 
melanoma 
Phase I Dendritic cells transfected with TERT, Survivin and p53 
mRNA (vaccine) 
NCT00425360 Pancreatic cancer Phase III GV1001 (TERT-based vaccine) + chemotherapy versus 
chemotherapy alone 
a
 GRN163L is also known as imetelstat. 
b
 This trial has been prematurely stopped in September 2012 due to the results of an unplanned interim analysis 






Figure 1. Telomeres, telomerase, and their relationship to cancer.  
 
The ends of chromosomes are organized in special heterochromatic structures called telomeres, 
which contain a double-stranded DNA region of TTAGGG repeats and a 150–200 nucleotide-long 
G-rich single strand. The G-rich overhang invades the doubled-stranded DNA region of the 
telomere to form a protective telomere T-loop (not shown). The T-loop of the telomere is boud by 
the shelterin complex, comprising the telomeric repeat binding factor 1 (TRF1), TRF2, repressor-
activator protein 1 (RAP1), protection of telomeres protein 1 (POT1), TIN2 organizing protein 
(TPP1), and TIN2. POT1 binds to the 3′ singled-stranded overhang of the DNA repeats, and TRF1 
and TRF2 bind to telomeric double-stranded DNA. TIN2 then binds TRF1 and TRF2 and recruits 
the TPP1–POT1 complex. Telomerase is a two-component enzyme composed of a catalytic protein 
subunit (TERT) and the RNA template (TERC); it recognizes the 3′ hydroxyl group at the end of 
the G-rich overhang and elongates the telomere. Telomeric DNA uncapping – that is, the loss of 
normal telomere structure due to either the loss of telomeric repeat sequences or alteration in 
telomere proteins – can originate from different mechanisms. For example, oncogene-induced 
replicative stress may include the intrinsic telomere shortening that is associated with cell 
replication. Dysfunctional telomeres elicit a DNA damage response (DDR) through the activation 
of upstream kinases, including DNA-dependent protein kinase (DNA-PK) and the ataxia-
telangiectasia mutated (ATM) and ataxia-telangiectasia related (ATR) kinases. The DDR can have 
two opposing outcomes depending on the status of checkpoints usually mediated by tumor 
suppressor genes (e.g., p53 and p21). p53 activation induces cell cycle arrest, apoptosis, or 
senescence, negatively affecting stem cell functionality and causing tissue degeneration and, 
ultimately, organ failure. In p53-deficient cells, the damage proceeds unchecked: the activation of 
the ATM and ATR kinase pathways leads to mitotic block and cells can then by-pass mitosis and 
re-enter the S-phase of the cell cycle, becoming polyploid. Polyploidization can lead to genomic 
instability due to the presence of multiple centrosomes, which will give rise to the random 
distribution of chromosomes and create aneuploid daughter cells during mitosis. Activation of the 
non-homologous end joining (NHEJ) pathway leads to end-to-end fusions that initiate cycles of 
breakage–fusion–bridges. Upon telomere healing, either by telomerase reactivation or by 
homologous recombination-based mechanisms (e.g., the alternative lengthening of the telomere, 
ALT), indefinite cell cycling is allowed and stable malignant clones can be generated. 
 23 
 
Figure 2. Schematic view of five telomerase-targeting anticancer strategies.  
 
(a) Given that the telomerase genes TERT and TERC are actively expressed by most malignant 
cells, vectors designed to encode either oncolytic viruses or suicide genes driven by the TERT or 
TERC promoters can selectively kill cancer cells. (b) Gene therapy tools such as antisense-
oligonucleotides (ASO), small interfering RNAs (siRNAs), or ribozymes can selectively neutralize 
the mRNA molecules encoding TERT or TERC, ultimately inhibiting telomerase expression. (c) 
TERT-specific small molecule inhibitors can block telomerase activity. (d) Telomeres, which are 
physiologically shortened by DNA replication during cell mitosis, can be lengthened by telomerase; 
however, if a drug stabilizes the G-quadruplex structures that are one of the two modes in which 
telomeres exist (along with T-loops, see text for more details), telomerase cannot access the G-rich 
3'-single strand overhang, which ultimately prevents telomere elongation. (e) TERT protein is 
degraded by the proteasome, which generates TERT peptides. These peptides are presented on the 
surface of cells expressing telomerase (such as malignant cells) by class I HLA molecules. If active, 
specific immunotherapy (i.e. vaccination) regimens elicit an effective immune response to these 






ASO (anti-sense oligonucleotide): a class of short strand deoxyribonucleotide analogues that 
sequence-specifically hybridize with complementary mRNA via Watson-Crick base pairing. 
Formation of the ASO–mRNA heteroduplex either triggers the activity of RNaseH (leading to 
mRNA degradation) or induces translational arrest by steric hindrance of ribosomal activity, 
ultimately downtregulating target protein expression and activity. 
BIBR1532: Non-competitive small molecule inhibitor of both TERT and TERC. 
BRACO19: a G-quadruplex stabilizer that potently inhibits telomerase. 
Cancer stem cell: An immortal cancer cell with self-renewing capacity and the ability to 
indefinitely sustain a tumor cell population. 
Cancer vaccine: A therapeutic preparation containing tumor-associated antigens (TAAs) – or 
peptides derived from these proteins – that elicit an adaptive immune response against malignant 
cells expressing those antigens. In dendritic cell-based vaccines, autologous dendritic cells are first 
loaded ex vivo with peptides or transfected with genes encoding tumor associated antigens and then 
injected into patients. 
Cell senescence: Cell cycle arrest following a limited number of cell divisions, typically triggered 
by one or more dysfunctional telomeres. 
Dendritic cells: Professional antigen presenting cells (APCs) that present protein-derived peptides 
loaded on class I and class II HLA molecules to CD8+ (cytotoxic) and CD4+ (helper) T-
lymphocytes, respectively. 
G-quadruplex: a four-stranded nucleic acid structure that consists of a square arrangement of 
guanines stabilized by Hoogsteen hydrogen bonds. G-quadruplex structures form within or between 
guanine-rich strands of DNA, including telomeres. 
GRNVAC1: Anticancer vaccine made of mature autologous (i.e., obtained from the patient) 
dendritic cells transfected with mRNA encoding a TERT-LAMP (lysosomal associated membrane 
protein) fusion construct. 
GV1001: Telomerase-based cancer vaccine made of a 16-mer TERT peptide. 
Imetelstat: an antisense oligonucleotide (also known as GRN163L) complementary to the TERC 
mRNA that inhibits telomerase expression. 
IRES (internal ribosomal entry site): a sequence within an mRNA that allows translation initiation 
independent of a 5'-terminal mRNA cap. 
Ribozyme: an RNA molecule with a well-defined tertiary structure that enables it to perform a 
chemical reaction; a catalytic RNA molecule. 
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siRNA (small interfering RNA): a class of double-stranded RNA 20–25 nucleic acids long that 
mediate RNA interference, that is, inhibition of the expression of specific genes or mRNAs by a 
complementary nucleotide sequence. 
Suicide gene: A gene that, when expressed, leads to death of the hosting cell. Expression of suicide 
genes is controlled by promoters that are preferentially activated in target cells. For example, TERC 
or TERT promoters are used within tumors. Examples of suicide genes are those that encode 
proteins that control the replication of oncolytic viruses or enzymes that convert a pro-drug into a 
toxic compound. 
Telomelysin: Attenuated adenovirus 5 vector, also known as OBP-301, in which the TERT 
promoter element drives expression of the E1A and E1B genes linked with an internal ribosome 
entry site (IRES). 
Telomerase: A ribonucleoprotein made of a protein (TERT) and an RNA component (TERC). Its 
best characterized activity is to elongate telomeres, but is also appears to have extra-telomeric 
functions.  
Telomere: The ends of linear chromosomes are made of repetitive TTAGGG DNA sequences 
associated with telomere binding proteins; this structure protects chromosome ends from being 
recognized as DNA double stand breaks by the DNA repair machinery. 
Telomere uncapping: Loss of proper telomere structure due to either severe loss of telomeric 
repeat sequences (telomere shortening) or alteration in telomeric proteins. In both cases a cascade of 
events called the DNA damage response (DDR) is elicited. 
Telomestatin: a small molecule G-quadruplex stabilizer that acts as a potent telomerase inhibitor. 
TERC: telomerase RNA component, the RNA template of telomerase. 
TERT: telomerase reverse transcriptase, the catalytic subunit of telomerase.  
Vx-001: Telomerase-based cancer vaccine made of a 9-mer TERT peptide modified at position 572 
to increase its immunogenicity. 
 
 
